💸 The Tape

Kentucky's medical cannabis program just went from one of the most restrictive in the country to one of the most rapidly expanding — and Governor Andy Beshear isn't waiting for the legislature to catch up.

On Tuesday, Beshear signed an executive order adding 15 new qualifying health conditions to the state's medical cannabis program, including Parkinson's disease, HIV/AIDS, sickle cell anemia, fibromyalgia, arthritis, and glaucoma. The governor framed the action not as an expansion but as a clarification — arguing that conditions involving symptoms like chronic pain and nausea, which are already covered under existing law, inherently include the diseases that produce those symptoms.

"Too much is at risk to just stand by and let the law's lack of clarity leave Kentuckians without relief," Beshear said. The administration estimates the executive order could make more than 400,000 additional Kentuckians eligible for the program — a massive expansion of the addressable patient population in a state where approximately 24,000 patients are currently enrolled.

And then the governor went further, saying publicly what few Southern Democratic officials have been willing to say: "I also think it's time for decriminalization. Nobody should be going to jail just because of marijuana."

From Crawl to Sprint

Kentucky's cannabis journey has been defined by patience tested to its limits. The state legalized medical cannabis in 2023, but the program didn't launch until January 1, 2025 — and even then, the rollout was painfully slow. The first dispensary didn't open until December 2025, and product availability remained limited well into the first quarter of 2026 as cultivators and processors worked through early harvest cycles and compliance protocols.

Beshear himself acknowledged the frustration in January, saying he was "not satisfied" with the pace but expected things to "pick up significantly" through 2026. That prediction has largely proven accurate. As of May 2026, the state has approved eight cultivators, two safety compliance facilities, one processor, and a growing number of dispensaries spread across the commonwealth — from Louisville and Lexington to smaller communities like Beaver Dam, Paducah, and Princeton.

The program now includes roughly 500 medical professionals authorized to recommend cannabis and 32 licensed cannabis businesses in various stages of operation. During the November 2024 election, more than 100 cities and counties approved local ordinances permitting medical cannabis businesses — a grassroots signal that even in conservative Kentucky, the political ground has shifted decisively.

Who's Operating — And Who Stands to Benefit

Kentucky's market structure is notably different from the large MSO-dominated landscapes in states like Florida or Pennsylvania. The program features a limited-license framework with tiered cultivation permits, and the operator base is a mix of local entrepreneurs and established multi-state companies.

On the dispensary side, the market includes operators like Speakeasy Dispensary, which operates locations in Lexington, Princeton, and Ashland under the AR-MO-KY-MS Cannabis Ventures umbrella. Kentucky Alternative Care (operated by Picasso Cannabis) serves Louisville from its Bardstown Road location. NuEra Frankfort (Canntucky Ventures) covers the state capital. Blue Sage Cannabis Company serves the Lexington suburbs from Nicholasville. The Post Dispensary (Tree Soft LLC) operates in Beaver Dam, and newer entrants like Nature Med in Paducah, Green Releaf Dispensary in Ferguson, and Yellow Flowers in Erlanger have opened in recent months.

On the cultivation side, the most significant MSO presence belongs to Cresco Labs, which announced a management services agreement in March 2025 to operate one of Kentucky's coveted Tier 3 cultivation licenses — the largest category, allowing up to 25,000 square feet of canopy. CEO Charlie Bachtell called Kentucky "our first of many opportunities to reinvest free cash flow back into high ROIC growth initiatives." Cresco completed its first Kentucky harvest in April 2026 and is now actively supplying the market.

Other cultivators approved to operate include L&O Legacies in Jessamine County, Best State in Lincoln County, Slaughter Branch in Hopkins County, and Goeing Blue (Farmtucky) in Jessamine County. Commonwealth Cannabis holds a license in Marshall County, and several additional licensees are in various stages of facility buildout and inspection.

Industry analysts have forecasted the Kentucky market to generate over $135 million in revenue by 2026, growing to more than $228 million by 2028. With the executive order potentially quadrupling the eligible patient population, those projections may prove conservative.

The Operators Best Positioned

The companies that stand to benefit most from Beshear's expansion are those that have already invested in production capacity and geographic coverage. Cresco Labs, with its Tier 3 cultivation license and established national brand portfolio — including Cresco, High Supply, and Mindy's — has the scale and product diversity to supply a rapidly growing patient base. The company's ability to bring proven SKUs from mature markets like Illinois and Pennsylvania into Kentucky gives it a significant advantage over smaller local operators still developing their product lines.

Speakeasy Dispensary's multi-location retail footprint across different regions of the state positions it to capture patient traffic as the registry expands geographically. And local operators who moved early — securing licenses, building facilities, and establishing patient relationships during the program's difficult first year — now have first-mover advantages that will be difficult for later entrants to replicate.

The Federal Backdrop

Beshear explicitly connected his state-level action to the federal rescheduling of medical cannabis to Schedule III, saying he supports the effort and noting that "in the very least, it will allow a lot more research." He also cited a University of Kentucky study linking the availability of regulated medical marijuana dispensaries to lower rates of opioid overdoses — a data point that resonates powerfully in a state that has been devastated by the opioid epidemic.

The governor's call for decriminalization adds another dimension. While recreational legalization remains unlikely in Kentucky's Republican-controlled legislature, Beshear is building a record of incremental executive action that continues to expand patient access and normalize cannabis within the state's healthcare framework.

The Bottom Line

Kentucky's medical cannabis program launched late, rolled out slowly, and operated under some of the most restrictive qualifying conditions in the country. In the span of six months, it has gone from a handful of dispensaries with limited product to a rapidly expanding market with growing patient enrollment, increasing production capacity, and a governor who just potentially quadrupled the eligible population with the stroke of a pen.

For operators already on the ground — particularly those with cultivation scale and established brand portfolios — the expansion represents exactly the kind of high-return growth opportunity that justified the early investment. For the 400,000 Kentuckians who may now qualify for medical cannabis, it represents something simpler: access to relief they've been waiting for.

"Somebody's listening," as one patient put it in another state. In Kentucky, the governor is making sure of it.

Source: Marijuana Moment

📈 Dog Walkers

$AYRWF ( ▼ 22.73% ) Closes Major Asset Transfer

The company announced the closing of transfers for its Florida, New Jersey, and Nevada operations into wholly-owned subsidiaries of Arboretum Bidco LLC, the entity established by AYR's senior secured noteholders to acquire the company's operating assets under a Master Purchase Agreement dated November 2025. Arboretum intends to continue operating under the "Ayr Wellness" trade name.

The latest closings follow the initial Virginia transfer completed earlier this year, meaning four of AYR's state-level operations have now moved into the Arboretum structure. Each transfer required state regulatory approval, all of which were obtained prior to closing. Florida, New Jersey, and Nevada represent the bulk of AYR's revenue-generating footprint — making these closings the most consequential milestones in the restructuring to date.

Meanwhile, the original AYR Wellness entity continues progressing through CCAA liquidation proceedings in the Supreme Court of British Columbia, winding down the corporate shell while the operating businesses live on under creditor ownership.

It's the same playbook outlined months ago: creditors take the keys, operations continue, the brand survives. For employees, patients, and customers in those three states, the transition should be functionally invisible. For former equity holders, the outcome is far less pleasant.

$OPTI.CSE ( ▲ 2.53% ) Hits Major Milestone

The commercial-stage pharmaceutical manufacturer announced the completion of a GMP production run of its 5mg psilocybin finished drug product — the same formulation already being prescribed to patients in Australia for treatment-resistant depression under the Therapeutic Goods Administration's Authorised Prescriber Scheme. The company also updated the product's bottling configuration to improve ease of use for Australian prescribers and patients.

What makes Optimi's model distinctive is the vertical integration. Every stage of manufacturing — biomass cultivation, API extraction using proprietary methods, encapsulation, and packaging — was completed in-house at the company's facility under its Health Canada Drug Establishment Licence (DEL). CEO Dane Stevens put it plainly: "Optimi is one of the only companies to take naturally derived psilocybin from biomass to a finished drug product, entirely under one roof and on our own licence."

Additional product from the same production run is earmarked for clinical research in the United States and clinical trials in Europe across various indications — meaning the same medicine reaching patients today is also supplying the studies that will define tomorrow's treatment protocols.

The facility itself is built to institutional standards, including a Health Canada-compliant Level 8 vault capable of securing controlled substances valued at up to C$100 million. Optimi is authorized to hold up to 20 kilograms of psilocybin and approximately 2,000 kilograms of biomass on site — genuine commercial-scale capacity in a sector where most competitors are still operating at bench scale.

In the psychedelic therapeutics space, the gap between companies with presentations and companies with products keeps widening. Optimi is on the product side — manufacturing at GMP scale, supplying regulated patients, and feeding clinical trials simultaneously. That's a rare position, and it's getting harder to replicate.

🗞️ The News

📺 Trade To Black

Building Verano for Wall Street: A Capital Markets Breakdown | TTB Presented by Flowhub

• Verano Reverse Split: CEO George Archos breaks down the company's 1-for-5 reverse stock split taking effect mid-June, following its 2025 redomiciling to Nevada — both deliberate steps toward a potential major U.S. exchange uplisting.

• Institutional Access: The conversation explores what Nasdaq or NYSE listing could mean for a company operating 162 dispensaries across 13 states, including broader investor access and improved cost of capital.

• DEA Hearing & 280E: Archos shares his perspective on the June 29 administrative hearing on broader rescheduling and how 280E tax relief from the existing medical reclassification is already impacting operator balance sheets.

• Industry-Wide Positioning: The discussion covers the wave of reverse splits and cap-table cleanups across the sector, ongoing legal challenges to rescheduling in the courts, and where Archos sees the next phase of cannabis industry growth.